{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:49:20Z","timestamp":1789544960458,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Copenhagen University"},{"name":"Danish Council for Independent Research\u2013Medical Sciences"},{"name":"Region Hovedstadens Forskningsfond"},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jhep.2018.10.031","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T02:16:11Z","timestamp":1541211371000},"page":"388-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape"],"prefix":"10.1016","volume":"70","author":[{"given":"Long V.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Brun","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Schou","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Humes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie B.N.","family":"Serre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-305X","authenticated-orcid":false,"given":"Kristian","family":"Sch\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-4806","authenticated-orcid":false,"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-0256","authenticated-orcid":false,"given":"Judith M.","family":"Gottwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.10.031_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0010","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.10.031_b0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jhep.2018.10.031_b0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0035","unstructured":"AASLD-IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. https:\/\/www hcvguidelines org\/ Accessed July 9, 2018."},{"key":"10.1016\/j.jhep.2018.10.031_b0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2018.10.031_b0045","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0050","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0055","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1128\/AAC.01444-15","article-title":"In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants","volume":"59","author":"Verbinnen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0060","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JVI.02877-14","article-title":"Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77","volume":"89","author":"Li","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2018.10.031_b0065","doi-asserted-by":"crossref","first-page":"19757","DOI":"10.1073\/pnas.1218260109","article-title":"Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2018.10.031_b0070","doi-asserted-by":"crossref","first-page":"e00037","DOI":"10.1128\/AAC.00037-17","article-title":"Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors","volume":"61","author":"Pham","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0075","first-page":"E1101","article-title":"Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2018.10.031_b0080","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jhep.2018.10.031_b0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2013.11.009","article-title":"Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.10.031_b0090","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.10.031_b0095","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance","volume":"59","author":"Jensen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140912","article-title":"Creation of functional viruses from non-functional cDNA clones obtained from an RNA virus population by the use of ancestral reconstruction","volume":"10","author":"Fahnoe","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2018.10.031_b0105","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/ncomms3636","article-title":"Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses","volume":"4","author":"Wilker","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2018.10.031_b0110","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants. in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle","volume":"60","author":"Serre","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.10.031_b0120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.24172","article-title":"Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)","volume":"53","author":"Imhof","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.10.031_b0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.antiviral.2018.07.014","article-title":"Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: essential tools in testing of antivirals and emerging vaccine strategies","volume":"158","author":"Ramirez","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2018.10.031_b0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.meegid.2017.05.007","article-title":"Exploring resistance pathways for first-generation NS3\/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning","volume":"53","author":"Cuypers","year":"2017","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jhep.2018.10.031_b0135","doi-asserted-by":"crossref","first-page":"D363","DOI":"10.1093\/nar\/gkl970","article-title":"euHCVdb: the European hepatitis C virus database","volume":"35","author":"Combet","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2018.10.031_b0140","doi-asserted-by":"crossref","first-page":"D512","DOI":"10.1093\/nar\/gkm962","article-title":"The hepatitis C sequence database in Los Alamos","volume":"36","author":"Kuiken","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2018.10.031_b0145","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1128\/AAC.03534-14","article-title":"Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents","volume":"58","author":"Wose Kinge","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0150","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/JCM.00238-16","article-title":"Sequencing analysis of NS3\/4A, NS5A, and NS5B genes from patients infected with hepatitis C virus genotypes 5 and 6","volume":"54","author":"Ku","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2018.10.031_b0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2\u20136 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0160","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0165","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0170","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/S0168-8278(15)31102-8","article-title":"Preclinical profile of the pan-genotypic HCV NS3\/4A protease inhibitor GS-9857","volume":"62","author":"Taylor","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0175","doi-asserted-by":"crossref","first-page":"e01620","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C Virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0180","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jvh.12527","article-title":"GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study","volume":"23","author":"Rodriguez-Torres","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2018.10.031_b0185","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0190","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.10.031_b0195","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2017.01.050","article-title":"Safety and efficacy of elbasvir\/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis","volume":"152","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.10.031_b0200","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41395-018-0053-4","article-title":"Elbasvir\/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2\/3 clinical trials","volume":"113","author":"Zamor","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.10.031_b0205","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2018.10.031_b0210","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02217-17","article-title":"Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.10.031_b0215","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.10.031_b0220","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1053\/j.gastro.2016.07.039","article-title":"Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial","volume":"151","author":"Lawitz","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2018.10.031_b0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3851\/IMP3202","article-title":"Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3\/4A protease inhibitor","volume":"23","author":"Lawitz","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2018.10.031_b0230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.10.031_b0235","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.10.031_b0240","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","article-title":"Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients","volume":"138","author":"Reesink","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.10.031_b9000","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","article-title":"HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models","volume":"154","author":"Pham","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818325157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818325157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:35:10Z","timestamp":1759174510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818325157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0168827818325157"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.10.031","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}